<DOC>
	<DOCNO>NCT01436201</DOCNO>
	<brief_summary>The purpose study study body process digoxin effect dulaglutide digoxin process body . Information side effect may occur also collect . This study research purpose intend treat medical condition . This research study require blood sample obtain stored future research involve genetic analysis .</brief_summary>
	<brief_title>A Study Effect Dulaglutide How Body Handles Digoxin Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination Male participant female partner childbearing potential , partner pregnant breastfeeding , agree use reliable method contraception time first dose 3 month last dose investigational product , determine investigator . The method may one following : Condom spermicidal agent Male participant sterilization True abstinence ( line participant 's usual lifestyle choice ; withdrawal calendar method consider acceptable ) Female participant childbearing potential ( , postmenopausal permanently sterilize [ , tubal occlusion , hysterectomy , bilateral salpingectomy ] ) . Such participant require use contraception must test negative pregnancy time enrolment . Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) least 1 year spontaneous amenorrhea , follicle stimulate hormone ( FSH ) ≥40 milliinternational unit per milliliter ( mIU/mL ) Female participant undergone sterilization tubal ligation agree use condom conjunction spermicidal gel , foam , cream , film suppository time screen 3 month last dose investigational product . Such participant must also test negative pregnancy time enrolment Have body mass index ( BMI ) 18.5 32.0 kilogram per square meter ( kg/m^2 ) , inclusive , screen Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator ( potassium , magnesium , calcium value must within normal range ) Have normal renal function define estimate creatinine clearance ( CrCl ) ≥80 milliliter per minute ( mL/min ) Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study restriction Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy glucagon like peptide1 ( GLP1 ) relate compound include dulaglutide ( LY2189265 ) digoxin , related compound component either formulation Are participants previously complete withdrawn study study investigate dulaglutide 3 month prior screen receive glucagonlike peptide incretin mimetics 3 month prior screen Have abnormality 12lead electrocardiogram ( ECG ) ( , first , second , third degree atrioventricular [ AV ] block , prolong correct QT [ QTc ] interval , sinus tachycardia , sinus bradycardia , atrial fibrillation , sinus node disease ) , opinion investigator , increase risk associate participate study Have history significant dysrhythmias AV block Have abnormal blood pressure ( least 5 minute sit ) , opinion investigator , increase risk associate participate study Have history presence cardiac , respiratory , hepatic , renal , endocrine ( , hypothyroidism ) , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , example relevant esophageal reflux gall bladder disease , gastrointestinal disease impact gastric empty ( GE ) ( , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate GLP1 analog . Participants dyslipidemia , participant cholecystolithiasis ( removal gall stone ) and/or cholecystectomy ( removal gall bladder ) past , sequela , may include study discretion screen physician Show evidence significant active neuropsychiatric disease Have family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Have use intend use overthecounter medication acetaminophen within 7 day prior dose prescription medication ( exception vitamin/mineral supplement ) within 14 day prior dose , use St John 's Wort within 14 day prior dose Have donate blood 500 mL within month prior screen Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption screen followup ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Are smoker Have history cancer past 20 year , exception basal cell squamous cell skin cancer , treat cervical carcinoma situ Intend consume grapefruit within 7 day prior dose Are participant , opinion investigator , way unsuitable participate study Have medical condition , medical history take medication contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>